Morgan Stanley
NBP

Morgan Stanley’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Morgan Stanley’s Portfolio NBP Stock Details NBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.12M Sell
3,653,228
-184,970
-5% -$377K ﹤0.01% 3979
2026
Q1 		$9.44M Buy
3,838,198
+52,696
+1% +$176K ﹤0.01% 3610
2025
Q4 		$15.1M Buy
3,785,502
+1,553,462
+70% +$6.87M ﹤0.01% 3195
2025
Q3 		$8.44M Buy
2,232,040
+2,173,745
+3,729% +$7.38M ﹤0.01% 3685
2025
Q2 		$141K Buy
58,295
+23,478
+67% +$31.9K ﹤0.01% 5996
2025
Q1 		$28.7K Sell
34,817
-3,508,567
-99% -$3.33M ﹤0.01% 6445
2024
Q4 		$3.01M Buy
3,543,384
+3,512,737
+11,462% +$3.91M ﹤0.01% 4400
2024
Q3 		$38K Buy
30,647
+16,767
+121% +$21K ﹤0.01% 6289
2024
Q2 		$23.2K Buy
13,880
+3,771
+37% +$6.74K ﹤0.01% 6409
2024
Q1 		$18.8K Sell
10,109
-506,587
-98% -$934K ﹤0.01% 6509
2023
Q4 		$982K Sell
516,696
-471,985
-48% -$705K ﹤0.01% 4936
2023
Q3 		$1.31M Buy
988,681
+544,491
+123% +$1.2M ﹤0.01% 4643
2023
Q2 		$1.33M Sell
444,190
-670,982
-60% -$2.16M ﹤0.01% 4659
2023
Q1 		$3.86M Sell
1,115,172
-476,099
-30% -$2.31M ﹤0.01% 3987
2022
Q4 		$6.65M Sell
1,591,271
-301,533
-16% -$1.14M ﹤0.01% 3482
2022
Q3 		$7.59M Sell
1,892,804
-483,164
-20% -$3.67M ﹤0.01% 3259
2022
Q2 		$26.8M Buy
2,375,968
+751,560
+46% +$9.01M ﹤0.01% 1965
2022
Q1 		$26.4M Buy
1,624,408
+166,052
+11% +$4.26M ﹤0.01% 1832
2021
Q4 		$69.1M Buy
1,458,356
+24,544
+2% +$1.47M 0.01% 1142
2021
Q3 		$104M Buy
1,433,812
+961,765
+204% +$69.5M 0.01% 824
2021
Q2 		$39.6M Buy
472,047
+240,741
+104% +$15.9M 0.01% 1494
2021
Q1 		$11.2M Buy
231,306
+42,070
+22% +$2.28M ﹤0.01% 2532
2020
Q4 		$8.92M Buy
189,236
+27,483
+17% +$1.08M ﹤0.01% 2637
2020
Q3 		$7.61M Sell
161,753
-13,376
-8% -$441K ﹤0.01% 2284
2020
Q2 		$5.24M Buy
175,129
+129
+0.1% +$2.67K ﹤0.01% 2611
2020
Q1 		$2.27M Buy
+175,000
New +$2.19M ﹤0.01% 3249

Other funds holding NBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
ACM
AIHC Capital Management Central $104M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley's NBP Position: Q2 2026 in Review

Morgan Stanley reduced its NovaBridge Biosciences American Depositary Shares (NBP) stake by 4.8% in Q2 2026, selling an estimated $377K and leaving 3,653,228 shares worth $7.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3979.

Morgan Stanley first reported a position in NBP in Q1 2020 and has held it in 26 quarters since. The position peaked at $104M in Q3 2021. 49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

  • Morgan Stanley held 3,653,228 shares of NovaBridge Biosciences American Depositary Shares worth $7.12M as of Q2 2026.
  • Morgan Stanley sold 184,970 NovaBridge Biosciences American Depositary Shares shares in Q2 2026, an estimated $377K.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3979 holding.
  • Morgan Stanley first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2020 and has held it in 26 quarters since.
  • Morgan Stanley's NovaBridge Biosciences American Depositary Shares position peaked at $104M in Q3 2021.
  • 49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.